Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Wachstum
Das Unternehmen befindet sich in einer Wachstumsphase, wobei das aktuelle Jahreseinkommen insgesamt 5.31M USD beträgt.
Überbewertet
Der aktuelle PE1 des Unternehmens liegt bei -1.082, im 3-Jahres-Hoch Prozentbereich.
Institutionelle Verkäufe
Die neuesten institutionellen Bestände sind 94.38K Aktien, was einen Rückgang von 72.64% im Vergleich zum Vorquartal darstellt.